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Abstract. 
Staphylococcus aureus infection is a persistent threat in resource-restricted settings in southeast Asia but informative 
data about this disease remain limited. We analyzed characteristics, management, and predictors of outcome in 
severely septic patients with community-onset S. aureus infection in northeast Thailand. We performed a 
prospective, multicenter observational cohort study of community-onset S. aureus sepsis in four referral hospitals 
recruiting patients at least 14 years of age admitted between March 2010 and December 2013. One hundred and 
nineteen patients with severe staphylococcal sepsis were enrolled. Diabetes was the most common underlying 
condition. Methicillin-resistant infection was rare. Twenty-eight-day mortality was 20%. Ninety-two percent of 
patients received appropriate antibiotic therapy and 82% were administered intravenous fluids on the first hospital 
day, although only 14% were managed in an intensive care unit (ICU). On univariable analysis, clinical variables at 
enrollment significantly associated with death at 28 days were coagulopathy or respiratory failure. Plasma 
interleukin (IL)-8 concentration alone accurately predicted mortality (area under the receiver operating curve = 0.82, 
95% confidence interval = 0.73–0.90). In multivariable analysis, addition of IL-8 concentration to a mortality 
prediction model containing clinical variables further improved the predictive ability of the model. We conclude that 
severe staphylococcal sepsis in northeast Thailand causes significant mortality. Diabetes is a common preexisting 
condition and most patients are managed outside the ICU even if they receive vasoactive/inotropic agents or 
mechanical ventilation. While clinical factors apparent on presentation including coagulopathy and respiratory 
failure predict death, plasma IL-8 improves this prediction. 
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INTRODUCTION 
Staphylococcus aureus is an established pathogen in resource-restricted regions of southeast 
Asia
1–4
 and an increasingly important contributor to the substantial global burden of severe 
sepsis—the syndrome of infection accompanied by a dysregulated host inflammatory response 
and organ dysfunction.
5,6
 Staphylococcus aureus expresses numerous virulence determinants that 
result in infection of the skin and soft tissues, respiratory tract, bones, joints, and endovasculature 
leading to sepsis.
7,8
 Yet few studies address management of hospitalized patients with severe 
sepsis—due to S. aureus or to other pathogens—in resource-restricted settings in southeast Asia 
or elsewhere. In addition to appropriate antibiotic therapy and drainage of infected spaces, 
intravenous fluids, vasopressor and inotropic agents, and mechanical ventilation are often 
required for these individuals. In a resource-restricted environment, robust data about 
presentation, management, and outcomes of these patients are essential to inform strategies to 
allocate scarce resources judiciously and improve outcomes.
9,10
 Central to this process is 
understanding what factors may predict outcome. Presently, the predictors of outcomes such as 
death from severe sepsis in resource-restricted settings are largely unknown. 
Thailand is a middle-income country in southeast Asia.
11
 The poorest and most populous area 
is in the northeast (http://documents.worldbank.org/curated/en/2005/11/7283755/thailand-
northeast-economic-development-report). Here, studies of community-acquired bacteremia show 
that S. aureus is the most common Gram-positive etiology and the third most common etiology 
overall after Escherichia coli and Burkholderia pseudomallei.
12,13
 In Cambodia, S. aureus is the 
most common Gram-positive etiology of bacteremia.
2,3
 Analysis of resistance patterns of 
community-acquired bacteremia isolates in northeast Thailand indicates that methicillin-resistant 
S. aureus (MRSA) is infrequent.
13
 This contrasts with data from Cambodia, where MRSA is 
more common.
2,3
 A single center study in northeast Thailand from 2006 to 2007 that evaluated 
outcome following invasive S. aureus infection identified a 26% mortality rate associated with 
this disease.
14
 Nineteen percent of these cases reflected hospital-acquired infection, and the 
mortality rate was significantly higher (52%) in this subset.
14
 To better characterize the impact of 
community-onset S. aureus sepsis at a regional level, we subsequently conducted a prospective 
multicenter study at four hospitals in three northeastern Thai provinces. These hospitals all have 
intensive care units (ICUs) where care is provided by specialized teams of doctors and nurses in 
higher provider-to-patient ratios. Patients at all hospitals can receive mechanical ventilation and 
vasoactive agents in the ICUs and on the general wards. Mechanical ventilators may be powered 
by gas (pneumatic) or electricity. Some data from this study have previously been reported, 
including our finding that some isolates identified as S. aureus are in fact Staphylococcus 
argenteus, a new pathogenic species that is misidentified as S. aureus in clinical diagnostic 
laboratories using standard identification tests.
15
 In light of the lack of distinction between these 
organisms in the clinical diagnostic laboratories, we included both S. aureus and S. argenteus 
isolates in this study. 
We used this study cohort to pursue three objectives. First, we aimed to characterize patients 
presenting with severe community-onset staphylococcal sepsis in northeast Thailand, including 
their clinical management and outcome. Second, we sought to identify clinical predictors of 
death in this setting. Third, we evaluated whether biological markers could augment the clinical 
prediction of death. Our findings provide key insights into severely ill patients with 
staphylococcal infection in a resource-restricted setting in southeast Asia. 
MATERIALS AND METHODS 
Study setting and design. 
A prospective observational study of community-onset invasive staphylococcal sepsis was 
conducted at four hospitals across northeast Thailand between March 2010 and December 2013. 
Study sites were Sunpasitthiprasong Hospital, Ubon Ratchathani; Udon Thani Hospital, Udon 
Thani; Srinagarind Hospital, Khon Kaen; and Khon Kaen Hospital, Khon Kaen. Potential study 
patients were identified by daily screening at each hospital diagnostic microbiology laboratory 
for clinical samples taken from a normally sterile site that grew a pure culture identified by the 
routine microbiology laboratory as S. aureus using methods derived from the Work Manual for 
Laboratory Identification of Bacteria and Fungi for Regional and General Hospitals, Department 
of Medical Science, Ministry of Public Health, Thailand. Subsequently, 58/311 (19%) of 
available isolates tested were reidentified in a research laboratory as S. argenteus using pulsed-
field gel electrophoresis and multilocus sequence typing.
15
 Inclusion criteria were as follows: age 
at least 14 years (age of admission to adult wards), community-onset infection (positive culture 
taken within 2 days of hospital admission, or after 2 days when sampling was delayed from a 
patient admitted with suspected infection), and at least two of four systemic inflammatory 
response syndrome criteria met within 48 hours of culture (the definition of sepsis at the time the 
study was performed).
16
 Severe sepsis was defined at enrollment as systolic blood pressure < 90 
or use of vasoactive agents, creatinine  2 mg/dL without a history of preexisting renal disease, 
bilirubin  2 mg/dL without a history of preexisting liver disease, platelet count  100,000/L, 
prothrombin time  20 seconds, respiratory failure requiring invasive mechanical ventilation, or 
Glasgow Coma Scale (GCS)  12.17 Laboratory data were available to make this determination 
as follows: creatinine, 312/327 patients; bilirubin, 134/327; platelet count, 323/327; and 
prothrombin time, 100/327. Exclusion criteria were other active coinfections potentially 
contributing to the clinical presentation, therapeutic immunosuppression with high-dose steroids 
or chemotherapy, and pregnancy. Patients were enrolled after providing written informed 
consent. A blood sample was drawn at the time of enrollment. 
Clinical and microbiological information for the hospitalization was obtained from the 
medical records. Mortality was ascertained in person or by telephone 28 days from the day of 
admission. No participants were lost to follow-up. 
Biomarkers. 
Tumor necrosis factor (TNF)-, interleukin (IL)-1, IL-6, and IL-8 concentrations in plasma 
obtained at enrollment were determined by enzyme-linked immunosorbent assay (TNF-, IL-1 
and IL-6, BD Bioscience, CA; IL-8, R and D Systems, MN). Lower limits of detection were 7.8 
pg/mL, 3.9 pg/mL, 4.7 pg/mL, and 15.6 pg/mL, respectively. 
Ethics. 
Ethical approval was obtained from the following ethical and scientific review committees: 
Faculty of Tropical Medicine, Mahidol University (approval no. MUTM 2011-007-01); 
Sunpasitthiprasong Hospital, Ubon Ratchathani (approval no. 004/2553); Udon Thani Hospital, 
Udon Thani (approval no. 0027.102/2349); Khon Kaen Hospital, Khon Kaen; and Faculty of 
Medicine (Srinagarind Hospital), Khon Kaen University, Khon Kaen, Thailand (approval no. 
HE541113). Subjects or their representatives provided written informed consent. 
Statistical analysis. 
Continuous variables are reported as the mean and standard deviation for normally 
distributed data or median and interquartile range (IQR) for nonnormally distributed data. 
Plasma cytokine concentrations were available for 118/119 patients with severe sepsis and were 
log10 transformed before analysis. Missing values for GCS and laboratory tests were treated as 
normal in the determination of organ failure as noted in Supplemental Table 1. Univariable 
analyses were performed with logistic regression. Multivariable analyses were performed with 
multiple logistic regression. Linearity of continuous variables was evaluated using the Box–
Tidwell procedure, and IL-8 and IL-6 were log10 transformed. A model of clinical predictors of 
death was developed using a backward elimination procedure on all variables collected or 
derived at enrollment reported in the univariable analysis with P < 0.1. Variables were 
sequentially removed based on the highest P value, until all variables retained had P < 0.05. Sex 
was also included as a variable given that IL-8 concentrations were higher in men. Internal 
validation of the selected predictors in the candidate model was performed by conducting 100 
bias corrected and accelerated bootstrap replications, and evaluating the confidence intervals 
(CIs) around the coefficients of the predictors. The model was evaluated for multicollinearity and 
specification error, and assessed using Hosmer and Lemeshow goodness of fit testing. 
Differences in the model including log10 IL-8 or log10 IL-6 were determined by examining the 
Akaike information criterion (AIC) and Bayesian information criterion (BIC), by performing a 
likelihood ratio test, and by comparing areas under the receiver operating curves (ROCs). All 
statistical analyses were conducted using Stata v14.2 (StataCorp LP, College Station, TX). 
RESULTS 
Characteristics of enrolled patients. 
Three hundred and twenty-seven patients meeting Staphylococcus sepsis criteria were 
enrolled. Of these, 119 (36.4%) met the criteria for severe sepsis (Figure 1). Clinical 
characteristics of the patients with severe sepsis are shown in Table 1. The median age was 58.5 
years (IQR = 46–67) and 80 (67.2%) were male. The median duration of symptoms was 4 days 
(IQR = 2–7). Seventy-three (61.3%) patients had an underlying medical condition. The most 
common preexisting conditions were diabetes (N = 42, 35.3%) and kidney disease (N = 23, 
19.3%). Seventy-six (63.9%) patients with severe sepsis had positive blood cultures at the time 
of enrollment; the remaining patients had positive cultures of pus specimens. Bacterial isolates 
from three patients (2.5%) were MRSA. 
Organ failure in patients with severe staphylococcal sepsis. 
Organ failure in patients with severe sepsis at the time of enrollment is shown in 
Supplemental Table 1. Respiratory failure (N = 46, 38.7%) and shock (N = 45, 37.8%) were the 
most common manifestations of severe sepsis. Thrombocytopenia (N = 34, 28.6%) and acute 
kidney injury (N = 30, 25.2%) were also frequent. 
Clinical management and outcome of patients with severe staphylococcal sepsis. 
Specific therapies provided for the management of severe sepsis, including antibiotics and 
drainage procedures, intravenous fluid resuscitation, and organ support measures are shown in 
Table 1. Most patients (N = 109, 91.9%) received antistaphylococcal antimicrobial therapy by 
the first day of hospital admission. Of the 10 patients in whom appropriate therapy was delayed 
or not initiated, two had MRSA. Vancomycin was administered to 21 (17.6%) of patients. A 
drainage procedure was performed on 50 (42.0%) patients. Most patients (N = 97, 81.5%) 
received intravenous fluids on the first hospital day. Seventeen (14.3%) patients were admitted to 
ICUs; the remaining patients were managed on general wards. These patients did not differ by 
age, sex, or underlying medical condition. Only patients requiring mechanical ventilation were 
admitted to ICUs but the majority of patients (N = 34, 66.7%) requiring mechanical ventilation 
were cared for on the general wards. 
Hospital mortality was 14.3% and 28-day mortality was 20.2% among severe sepsis patients 
(compared with 2.9% 28-day mortality in patients with nonsevere sepsis). One of three (33.3%) 
patients with MRSA died within the 28-day study period. Twenty-eight-day mortality was 52.9% 
in patients admitted to an ICU but 14.7% in patients managed on the general wards. 
Biomarkers in patients with severe staphylococcal sepsis. 
We measured the concentrations of four pro-inflammatory cytokines in patients’ plasma 
drawn at the time of enrollment: TNF-, IL-1, IL-6, and IL-8. We chose these biomarkers 
because of previous reports of their utility for sepsis detection or prognostication.
18
 All but one 
TNF- value and over 75% of IL-1 values were below the lower limit of detection of our assay 
so they were not analyzed further. In contrast, there was a marked range of IL-6 and IL-8 
responses across several orders of magnitude (Figure 2A). 
Univariable analysis of predictors of death in patients with severe staphylococcal sepsis. 
We then assessed which clinical factors were associated with 28-day mortality among 
patients with severe staphylococcal sepsis (Table 2). In univariable analyses, no preexisting 
condition was significantly associated with mortality, although the odds ratio (OR) for death for 
patients with heart disease was 3.60 (95% CI = 0.89–14.62, P = 0.07). At the time of enrollment, 
the presence of coagulopathy (OR = 5.44, 95% CI = 1.78–16.59, P = 0.003), or respiratory 
failure (OR = 1.33, 95% CI = 1.67–11.23, P = 0.003) were significantly associated with death. 
The association of altered mental status with death did not reach statistical significance (OR = 
2.97, 95% CI = 0.77–11.50, P = 0.12). During the hospitalization, any initiation of mechanical 
ventilation (OR = 7.48, 95% CI = 2.56–21.88, P < 0.001), or use of vasoactive agents (OR = 
3.52, 95% CI = 1.38–8.98, P < 0.001) was associated with death, but receipt of a drainage 
procedure was protective (OR = 0.29, 95% CI = 0.11–0.85, P = 0.02). Patients admitted to an 
ICU had greatly increased odds of death (OR = 6.53, 95% CI = 2.17–19.58, P = 0.001). 
We analyzed whether plasma cytokine concentrations predicted outcome in our cohort. Both 
IL-6 and IL-8 levels were strongly associated with death (OR = 3.91, 95% CI = 1.92–7.94, P = 
1.7 × 10
4
 and OR = 5.86, 95% CI = 2.52–13.63, P = 4.1 × 105), for log transformed IL-6 and 
IL-8 concentrations, respectively. Quartiles of IL-8 showed a stepwise increase in mortality rate 
(P for trend = 3.5 × 10
6
), whereas for IL-6, there was a more apparent threshold effect between 
the third and fourth quartiles (P for trend = 0.001) (Figure 2B and 2C). Next, we performed ROC 
analysis on the prediction of mortality by mediator concentrations. The AUROC for IL-6 was 
0.72 (95% CI = 0.59–0.85) (Figure 3A). The area under the ROC (AUROC) for IL-8 was 0.82 
(95% CI = 0.73–0.90) (Figure 3A). 
Multivariable analysis of predictors of death in patients with severe staphylococcal sepsis. 
We then performed multivariable regression of predictors of death among severe 
staphylococcal sepsis patients. To develop a model using clinical variables, we considered 
clinical data available at enrollment and included variables with P values < 0.1 in the initial 
model. We also included sex as IL-8 concentrations were higher in men. In the final model 
comprising clinical variables, coagulopathy and respiratory failure were independently 
associated with 28-day mortality (Table 3). The AUROC for mortality prediction by this baseline 
model was 0.75 (95% CI = 0.64–0.87) (Figure 3B). 
To determine the additional contribution of IL-6 and IL-8 as predictive biomarkers in this 
model, we repeated the model including these mediators individually and together. We found 
that the model including IL-6 had lower AIC and BIC scores than the baseline model (Table 3) 
and the two models were significantly different by the likelihood ratio test (P = 0.004). The 
AUROC for mortality prediction by the model including IL-6 was 0.81 (95% CI = 0.70–0.91) 
(Figure 3B), which was not significantly different from the baseline model (P = 0.12). Including 
IL-8 in the model instead of IL-6 resulted in a greater reduction of AIC and BIC scores (Table 
3), and this model was highly significantly different by the likelihood ratio test (P = 1.9 × 10
5
). 
The AUROC for mortality prediction by the model including IL-8 was 0.86 (95% CI = 0.78–
0.94) (Figure 3B), which was significantly different from the baseline model without IL-8 (P = 
0.03). There was no added benefit of adding IL-6 to a model with clinical variables and IL-8; the 
likelihood ratio test P = 0.29 and AUROC was 0.86 (95%CI = 0.78–0.94), P = 0.60 (Figure 3C). 
These results indicate the added benefit of including IL-8, but not IL-6, together with clinical 
variables as predictors of mortality. 
DISCUSSION 
Gram-positive organisms are important etiologies of sepsis in high-income countries.
5
 The 
available evidence indicates that staphylococcal infection is also of increasing concern in 
resource-restricted settings in Asia, including northeast Thailand.
1–4,12,13
 To our knowledge, our 
prospective multicenter study is one of the first to provide important data characterizing severe 
staphylococcal sepsis in such a setting. The major findings from our study are that severe 
staphylococcal sepsis causes significant mortality despite appropriate antibiotic therapy; diabetes 
is a common preexisting condition; most patients are managed outside the ICU even if they 
receive vasoactive/inotropic agents and mechanical ventilation; and while clinical factors 
apparent on presentation including coagulopathy and respiratory failure predict death, plasma IL-
8 significantly improves this prediction. 
In this multicenter study the 28-day mortality rate from severe staphylococcal sepsis was 
20%. A previous single center study in this region from 2006 to 2007 reported a mortality rate of 
20% at 12 weeks in hospitalized patients with non-nosocomial invasive S. aureus infection 
(defined as S. aureus cultured from a sterile site).
14
 In a related analysis of patients with S. 
aureus bacteremia—including nosocomial infection—who met criteria for severe sepsis, the 28-
day mortality rate was 53%.
19
 Together, these results underscore the significant burden of severe 
staphylococcal sepsis in northeast Thailand. They no doubt underestimate overall mortality, 
however, as these studies excluded patients who died before their cultures turned positive. The 
patients with severe staphylococcal sepsis in our study were older and mostly male. It is notable 
that nearly two thirds of patients had an underlying medical condition, and strikingly, diabetes 
was the predominant preexisting disease, present in over a third of patients. This not only reflects 
the increasing rates of noncommunicable chronic diseases such as diabetes worldwide,
20
 but may 
also indicate the impact of diabetes on susceptibility to bacterial infections such as S. aureus.
21
 
The management of severely septic patients with staphylococcal infection requires clinician 
awareness to diagnose severe sepsis, promptly administer appropriate antibiotics, drain pus, fluid 
resuscitate, and rigorously support failing organs.
19
 Although adherence to these basic tenets of 
sepsis management is essential, recent studies of severe sepsis in high-resource settings indicate 
that there is little benefit to an invasive early goal-directed care protocol.
22–24
 Most of the patients 
in our study received appropriate antimicrobial therapy and intravenous fluids within the first 
hospital day as well as access to surgical care and other organ support measures where necessary. 
MRSA was an uncommon cause of infection in our study but vancomycin, available at all sites, 
was administered quite frequently. While ICUs are also available at all the study sites, the large 
majority of patients enrolled were managed outside an ICU. Patients admitted to an ICU were 
more likely to have respiratory failure and more likely to die. Severely septic patients are often 
managed in ICUs in high-resource settings. Our observations suggest that ICU admission in this 
study was restricted to the subset of sickest patients, but that the majority of patients managed on 
general wards nonetheless received necessary therapies. 
We identified a number of risk factors for death from severe staphylococcal sepsis in 
northeast Thailand. In a multivariable analysis, the major clinical predictors on presentation to 
the hospital were coagulopathy and respiratory failure. These probably differ from a previous 
report of risk factors for death from S. aureus infection in northeast Thailand (in which age and 
cardiac disease were the presenting factors predicting death)
14
 due to our focus on community-
onset infection and patients with severe sepsis. In addition to these clinical risk factors, we also 
sought a biomarker that might serve as a useful adjunct predictor. If sufficiently accurate, such a 
biomarker could be assayed in a point-of-care device and therefore used by clinicians at the 
bedside in resource-restricted settings. The chemokine IL-8 is a fundamental participant in many 
inflammatory processes. It is produced by many different cells and is well described as a 
biomarker predicting outcome in sepsis,
25–29
 but not all reports support its utility as a risk 
stratification tool.
30
 We are not aware that it has previously been evaluated extensively in 
staphylococcal sepsis. We found that plasma levels of IL-8 provide accurate prediction of death, 
both alone and—crucially—when combined with clinical variables. Indeed, inclusion of IL-8 in 
the regression model substantially augmented the prediction of death compared with clinical 
variables alone. While plasma IL-6, TNF-, and IL-1 levels are also reported as predictors of 
death from sepsis,
31
 in our study the utility of IL-8 was much greater. Nonetheless, this finding 
requires external validation in other cohorts of severe staphylococcal sepsis. It also remains to be 
determined whether the characteristics of the clinical model will remain accurate in other causes 
of sepsis. If the predictive value of IL-8 is confirmed in these settings, it could serve to identify 
patients at high risk of death who deserve more intensive management upon recognition of 
sepsis. The low plasma concentrations of TNF- and IL-1 in our cohort mirror the findings of 
several other investigators,
32–34
 but it is also possible that levels of these mediators may have 
been higher earlier in the clinical course. 
Our study offers several strengths, including its prospective, multicenter design and excellent 
rate of follow-up. Our use of 28-day mortality rather than hospital mortality is especially 
important in this region where very ill patients are often taken home from the hospital to die. Our 
focus on staphylococcal sepsis addresses an important etiology of sepsis in the region, and it 
provides key insights into management of severe infection in provincial Thailand. Our 
investigation of IL-8 is important as this mediator has not been thoroughly evaluated as a 
biomarker in staphylococcal sepsis. 
The main limitation to our study was that we did not enroll patients until after a culture-
proven diagnosis of staphylococcal infection. Therefore, enrollment did not occur for at least 48 
hours into hospitalization and our figures are likely to underestimate early deaths. Some patients 
were enrolled even later when the bacterial isolation was further delayed. However, our mortality 
figures are similar to those in another prospective study of severe sepsis in this region that 
enrolled patients within 24 hours of admission (unpublished data). Although we enrolled patients 
with infection identified by the clinical laboratory as S. aureus, we recently reported that a subset 
of these patients actually was infected with a related pathogen, S. argenteus.
15
 Clinical 
manifestations of S. aureus infection may be more severe than S. argenteus infection,
15
 but as 
these are not differentiated in routine practice in this setting, we did not consider this in our 
analysis. Finally, the timing of antibiotic and intravenous fluid administration in our study is 
reported in days, whereas other studies support the importance of these treatments within hours 
of sepsis onset.
35
 
CONCLUSIONS 
We show that at least one in five patients with severe community-onset staphylococcal sepsis 
admitted to provincial hospitals in northeast Thailand country die. Many patients have diabetes, 
and most patients are managed outside ICUs. MRSA is uncommon. We define clinical risk 
factors for death and identify a highly predictive role for IL-8 that deserves further evaluation. 
These data expand our knowledge of severe staphylococcal sepsis in resource-restricted areas in 
southeast Asia. 
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FIGURE 1. Study flow chart. 
FIGURE 2. Plasma cytokine concentrations in patients with severe staphylococcal sepsis. (A) The distribution of 
interleukin (IL)-6 and IL-8 concentrations in study subjects. Boxes show 25th, 50th, and 75th percentiles. Bottom 
and top whiskers show 25th percentile minus 1.5 times the interquartile range (IQR) and 75th percentile plus 1.5 
times the IQR, respectively. (B) and (C) Mortality in patients with severe staphylococcal sepsis by quartile of IL-8 
(B) or IL-6 (C) concentrations. P for trend = 3.5 × 10
6
 and P for trend = 0.001, respectively. 
FIGURE 3. Receiver operating curves for prediction of death. (A) Log10 interleukin (IL)-6 (white circles) and log10 
IL-8 (black diamonds). (B) A baseline model of clinical variables (grey circles) with the addition of either log10 IL-6 
(white diamonds) or log10 IL-8 (black squares). (C) A model of clinical variables and log10 IL-8 (white circles) with 
the addition of log10 IL-6 (black diamonds). 
TABLE 1 
Baseline characteristics and management of patients with severe staphylococcal sepsis 
Variable N = 119 
Characteristic 
 Median age in years (IQR) 58.5 (46–67) 
 Female, no. (%) 39 (32.8) 
 Preexisting conditions, no. (%) 
  Diabetes mellitus 42 (35.3) 
  Kidney disease 23 (19.3) 
  Liver disease 12 (10.1) 
  Heart disease 9 (7.6) 
  Lung disease 7 (5.9) 
  Neurological disease 5 (4.2) 
  Alcoholism 4 (3.4) 
  Hematological disease 4 (3.4) 
  Cancer 2 (1.7) 
  Autoimmune disease 2 (1.7) 
  Median comorbidity index* (IQR) 1 (0–1) 
Intervention 
 Source control 
  Antistaphylococcal antibiotics on first hospital day, no. (%) 109 (91.9%) 
  Drainage procedure, no. (%) 50 (42.0%) 
  Days to drainage procedure, median (IQR) 1 (1–4) 
 Fluid resuscitation and organ support 
  Intravenous fluids on first hospital day 97 (81.5%) 
  Mechanical ventilation 51 (42.9%) 
  Gas powered ventilator 34 (28.6%) 
  Electrical ventilator 25 (21.0%) 
  Vasopressor or inotropic therapy 33 (27.7%) 
IQR = interquartile range. 
* Comorbidity index is a 10-point score comprising one point each for lung disease, heart disease, kidney disease, 
liver disease, neurological disease, hematological disease, autoimmune disease, cancer, diabetes, and alcoholism. 
TABLE 2 
Univariable analysis of predictors of death in severe staphylococcal sepsis 
Variable OR (95% CI) P value 
Baseline 
 Age 1.01 0.98–1.04 0.57 
 Female 1.63 0.65–4.09 0.30 
 Preexisting condition 
  Diabetes mellitus 1.13 0.45–2.85 0.80 
  Kidney disease 2.03 0.72–5.70 0.18 
  Liver disease 2.18 0.60–7.94 0.24 
  Heart disease 3.60 0.89–14.62 0.07 
  Lung disease 0.64 0.07–5.63 0.69 
  Neurological disease 0.99 0.11–9.28 0.99 
  Alcoholism –   
  Hematological disease 1.33 0.13–13.42 0.81 
  Cancer –   
  Autoimmune disease 4.09 0.25–67.82 0.33 
  Bacteremia 2.53 0.87–7.37 0.09 
Organ failure at enrollment 
 Respiratory failure 4.33 1.67–11.23 0.003 
 Shock 2.33 0.94–5.77 0.07 
 Thrombocytopenia 1.04 0.39–2.78 0.94 
 Acute kidney injury 0.99 0.35–2.77 0.98 
 Acute hepatic injury 0.90 0.24–3.45 0.88 
 Coagulopathy 5.44 1.78–16.59 0.003 
 Altered mental status 2.97 0.77–11.50 0.12 
Clinical management during hospitalization 
 Delayed antibiotics 0.99 0.20–4.99 0.99 
 Underwent drainage procedure 0.29 0.11–0.85 0.02 
 Received any intravenous fluid 3.65 0.45–29.36 0.22 
 Received mechanical ventilation 7.48 2.56–21.88 2.4 × 104 
 Received vasopressors or inotropes 3.52 1.38–8.98 0.008 
Biomarkers 
 IL-6 pg/mL (log10) 3.91 1.92–7.94 1.7 × 10
4
 
 IL-8 pg/mL (log10) 5.86 2.52–13.63 4.1 × 10
5
 
CI = confidence interval; IL = interleukin; OR = odds ratio. 
TABLE 3 
Multivariable analysis of predictors of death in severe staphylococcal sepsis 
Analysis Variable OR 95% CI P value 
Clinical 
variables 
without IL-8 
or IL-6 
Sex 1.75 0.62–4.96 0.29 
Respiratory failure 3.94 1.44–10.78 0.007 
Coagulopathy 6.04 1.77–20.57 0.004 
    
Model pseudo R
2
 = 0.15; AIC = 109.1; BIC = 120.2 
With IL-6 
Sex 1.87 0.63–5.53 0.26 
Respiratory failure 2.61 0.88–7.78 0.08 
Coagulopathy 4.41 1.09–15.76 0.04 
IL-6 pg/mL (log10) 2.74 1.31–5.75 0.008 
Model pseudo R
2
 = 0.22; AIC = 102.7; BIC = 116.5 
With IL-8 
Sex 3.89 1.05–14.37 0.04 
Respiratory failure 3.40 1.10–10.51 0.03 
Coagulopathy 5.62 1.44–21.87 0.01 
IL-8 pg/mL (log10) 7.57 2.71–21.20 < 0.001 
Model pseudo R
2
 = 0.31; AIC = 92.8; BIC = 106.6 
AIC = Akaike information criterion; BIC = Bayesian information criterion; CI = confidence interval; IL = 
interleukin; OR = odds ratio. 
SUPPLEMENTAL TABLE 1 
Organ failure in patients with severe staphylococcal sepsis 
Organ failure* N (%) 
Shock 45 (37.8) 
Acute kidney injury 30 (25.2) 
Acute hepatic injury 16 (13.5) 
Thrombocytopenia 34 (28.6) 
Coagulopathy 16 (13.5) 
Respiratory failure 46 (38.7) 
Altered mental status 10 (8.4) 
Thrombocytopenia is defined as platelets  100,000/L. Coagulopathy is defined as prothrombin time  20 seconds. 
Respiratory failure is defined as requiring invasive mechanical ventilation. Altered mental status is defined as 
Glasgow Coma Scale  12. 
* Shock is defined as systolic blood pressure < 90 or use of vasoactive agents. Acute kidney injury is defined as 
creatinine  2.0 mg/dL in patients without chronic kidney disease. Acute hepatic insufficiency is defined as bilirubin 
 2.0 mg/dL in patients without chronic liver disease. 
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